Authors: Disha Tiwari, Dipanjan Panda*, Atul Sharma, Dewesh Kishan
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a well-documented toxicity leading to dose limitation.Ibrutinib is an oral Bruton’s Tyrosine Kinase (BTK) inhibitor approved for treating chronic lymphocytic lymphoma. The most common neurological side effects of Ibrutinib include headache and dizziness. Herein, we report peripheral neuropathy as a dose-limiting manifestation of Ibrutinib treatment. Keywords: ChemotherapyÂinduced, Ibrutinib, Sensorimotor neuropathy, CLL, Side effect.
Open full article page